文献速递白血病

RNA聚合酶I与CDK联合疗法治疗侵袭性急性髓系白血病

Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia.
PubMed 文献 · Leukemia · 2026-10-08

研究通过FDA批准药物表型筛选,发现pan-CDK抑制剂Dinaciclib和Flavopiridol与CX-5461协同,在AML细胞系、小鼠模型及原代样本中增强疗效,机制涉及核仁应激通路激活和p53稳定化。

要点

  • Dinaciclib与CX-5461协同激活核仁应激通路,诱导凋亡和细胞周期阻滞。
  • 联合治疗显著改善小鼠AML模型生存并减少原代AML样本集落形成。
  • Pol I-CDK共靶向策略为侵袭性AML提供潜在临床转化方向。

核心结论

  • CX-5461与Dinaciclib或Flavopiridol联合可协同增强对侵袭性AML的治疗效果。

研究设计与样本

  • 对FDA批准药物进行表型筛选,以鉴定与CX-5461协同的化合物;在遗传多样性AML细胞系、小鼠AML模型和原代人类AML样本中验证。

主要发现

  • Dinaciclib在遗传多样性AML细胞系中表现协同作用,显著改善小鼠AML模型生存,并减少原代人类AML样本集落形成。
  • 协同作用至少部分归因于核仁应激通路的组合激活。
  • Dinaciclib驱动快速凋亡,CX-5461主要促进细胞周期阻滞,两者独立稳定p53但产生不同生物学结果,共同导致有效肿瘤清除并延迟治疗耐药发生。

临床怎么用

  • Pol I-CDK共靶向联合策略可能为侵袭性AML提供新的治疗选择,支持进一步临床转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite advances in therapy, specific subtypes of Acute Myeloid Leukemia (AML) remain largely incurable. The small molecule drug CX-5461 exhibits dual target specificity, acting as a first-in-class ribosome biogenesis inhibitor to induce the nucleolar surveillance pathway (NSP), as well as to poison Topoisomerase IIα (TOPIIA) to induce DNA damage. We conducted a phenotypic screen of FDA-approved drugs to identify compounds that synergies with CX-5461 to enhance the therapeutic efficacy of this drug in incurable AML. The pan-CDK inhibitors Dinaciclib and Flavopiridol were identified as efficient combinatorial therapies with CX-5461. Dinaciclib acts synergistically across a genetically divergent panel of human AML cell lines, significantly improves survival in murine AML models, and reduces colony formation in primary human AML samples. Synergy was attributable, at least partially, to combinatorial activation of the NSP. Both agents independently stabilized p53 but produced distinct biological outcome; Dinaciclib driving rapid apoptosis and CX-5461 primarily promoting cell-cycle arrest; which together yielded efficient tumor clearance and delayed onset of therapy resistance. These findings provide strong evidence that a combination treatment strategy that leverages nucleolar stress and cell cycle control to enhance treatment outcomes in AML, paving the way for clinical translation of Pol I-CDK co-targeting therapies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hein N, Poh P, Powell JA, et al. Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia. Leukemia. 2026. PMID: 42850350. doi:10.1038/s41375-026-03148-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。